Newly developed Alzheimer’s drugs that target amyloid proteins are under rigorous scientific examination following a critical review by Cochrane, a leading authority in evaluating medical evidence. The review suggests these biological drugs do not provide significant clinical benefits and are associated with high costs and severe side effects. In light of these findings, H2 Global Group, based in the Czech Republic, has proposed a novel alternative involving molecular hydrogen to the governments of all 27 EU member states.
On April 16, 2026, Cochrane released a comprehensive review of anti-amyloid monoclonal antibodies, focusing on patients with mild cognitive impairment and early-stage dementia due to Alzheimer’s disease. The analysis, which compiled data from 17 clinical trials with over 20,000 participants, found the effects of these drugs to be “trivial,” lacking any meaningful clinical impact. The review also pointed out a higher incidence of adverse effects such as brain swelling and microhemorrhages (ARIA). Lead author Francesco Nonino from the IRCCS Institute of Neurological Sciences in Bologna emphasized the need for Alzheimer’s research to explore alternative therapeutic pathways.
The global media and expert community have reacted strongly. Publications like The Guardian and Scientific American have described the drugs’ effects as “trivial” or “absent,” while The New York Times has highlighted the intense debate surrounding their clinical value. Experts such as Professor Robert Howard from University College London have criticized the overly optimistic portrayal of these drugs to patients’ families. Professor Paresh Malhotra from Imperial College London has also urged for research to move beyond the amyloid pathway. The drugs’ annual treatment cost, approximately €77,000 ($82,000 USD) per patient, presents a significant challenge for reimbursement in several European countries.
In response, H2 Global Group has put forward a strategic plan to EU leaders, advocating for a combination of molecular hydrogen therapy and VR cognitive rehabilitation. This approach is supported by a certified medical device already in use in over 40 European hospitals. Chief Medical Officer PharmDr. Milan Krajíček of H2 Global Group argues that solely focusing on beta-amyloid will not resolve Alzheimer’s disease. The company’s strategy, backed by a patent on the use of gaseous hydrogen in dementia treatment, aims to target oxidative stress and neuroinflammation in addition to neurodegeneration.
David Maršálek, CEO and Founder of H2 Global Group, suggests that the Czech Republic is uniquely positioned to lead a systemic solution to the challenge posed by an aging population and rising dementia cases. By leveraging Japanese-Czech technology and scientific evidence, along with an ongoing clinical study, Maršálek envisions a large-scale clinical trial spanning the EU. This initiative could offer a safe, effective, and accessible solution for millions of patients and their families, marking a significant shift in dementia treatment.